Calea and Fresenius Kabi Carbon Reduction Plan

Supplier name: Calea UK Limited
Publication date: 12 January 2022


The UK Government amended the Climate Change Act 2008 in 2019 introducing a target of at least a 100% reduction in the net carbon account (reduction of greenhouse gas emissions compared to 1990 levels) by 2050. This is the Net Zero Target. Calea UK Limited (Calea) is part of the Fresenius Kabi global healthcare organisation that specialises in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Calea is focused on the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi is a division of the healthcare group Fresenius SE & Co. KGaA. In the UK, FHC (Holdings) Limited is the holding company to two subsidiaries: Calea and Fresenius Kabi Limited (Fresenius Kabi). The two companies operate from two sites in Runcorn; these consist of warehouse space, offices, and an aseptic compounding unit. Calea is a specialised homecare company that provides care packages to meet specific patient needs. Calea is a large unquoted company under the Streamlined Energy and Carbon Reporting regulations by virtue of meeting both financial and employee thresholds.
Calea has reported most of its scope 1 and scope 2 emissions for the 2020 period under these regulations. This plan covers all scope 1 and 2 emissions in line with the GHG Protocol Corporate Standard and Action Note PPN 06/21. Work is currently being done to map scope 3 emissions and an interim report will follow.

Commitment to achieving Net Zero

Calea is committed to achieving Net Zero emissions by 2045.

To read the full report click here  Calea Carbon Reduction Plan 2020


HPN and Immunotherapy Homecare team call: 0800 121 8300
Biosimilars Homecare team call: 0800 090 2461